You are here

Anti-inflammatory Drug Discovery Using DictyoSuitelium

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1 R43 CA68916-01,
Agency Tracking Number: 29263
Amount: $100,000.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 1995
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
215 1st Street
Cambridge, MA 02142
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Lijun Wu
 () -
Business Contact
Phone: () -
Research Institution
N/A
Abstract

As critical components of cell-mediated immunity, chemokine and chemokine receptors play pivotal roleukocyte migration and cell adhesion. A long term objective is to discover and develop small molecucan block the binding of chemokine to its receptor or the downstream signaling pathways, and therebyan essential step in the inflammation process. DictyoSuitelium is a simple eukaryote that exhibits wresponses remarkably similar to that in leukocytes. The genetics and cell biology of DictyoSuiteliumsystem for reconstituting chemokine receptor-mediated signal transduction component and for developiscreening assay. The primary goal of this Phase I proposal is to test the feasibility of coupling ina model chemokine receptor, to the signal transduction cascade in DictyoSuitelium. Specifically, theIL8R-B will be expressed on cell surface of DictyoSuitelium; the mammalian Gai will be co-expressedbinding activity to IL8R will be determined; and the functional linkage between IL8R and adenylyl cyDictyoSuitelium will be tested.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government